Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AZD5991 + Capivasertib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD5991||AZD-5991|AZD 5991||MCL1 Inhibitor 18||AZD5991 binds to and inhibits Mcl1, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) DDT01-02, PMID: 32204955).|
|Capivasertib||Truqap||AZD5363|AZD 5363|AZD-5363||Akt Inhibitor (Pan) 21||Truqap (capivasertib) decreases PI3K/AKT/mTOR signaling by inhibition of AKT1, AKT2, and AKT3, potentially resulting in decreased cell proliferation (PMID: 22294718, PMID: 32532747, PMID: 32312891). Truqap (capivasertib) in combination with Faslodex (fulvestrant) is FDA-approved for use in patients with hormone receptor-positive, ERBB2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PTEN inact mut||breast cancer||predicted - sensitive||AZD5991 + Capivasertib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination of AZD5991 and Truqap (capivasertib) synergistically inhibited proliferation and induced apoptosis in a triple-negative breast cancer cell line and hormone-receptor positive breast cancer cell line each harboring a PTEN inactivating mutation in culture and inhibited tumor growth in cell line xenograft models (PMID: 36241868).||36241868|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|